Investigational Drug Information for Apabetalone
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Apabetalone?
Apabetalone is an investigational drug.
There have been 8 clinical trials for Apabetalone.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2015.
The most common disease conditions in clinical trials are Hypertension, Cardiovascular Diseases, and Familial Primary Pulmonary Hypertension. The leading clinical trial sponsors are Resverlogix Corp, ICON plc, and Medidata Solutions.
There are thirty-seven US patents protecting this investigational drug and three hundred and fifty-four international patents.
Summary for Apabetalone
| US Patents | 37 |
| International Patents | 354 |
| US Patent Applications | 173 |
| WIPO Patent Applications | 123 |
| Japanese Patent Applications | 28 |
| Clinical Trial Progress | Phase 3 (2015-11-01) |
| Vendors | 75 |
Recent Clinical Trials for Apabetalone
| Title | Sponsor | Phase |
|---|---|---|
| Apabetalone for Pulmonary Arterial Hypertension | Canadian Institutes of Health Research (CIHR) | Phase 2 |
| Apabetalone for Pulmonary Arterial Hypertension | Resverlogix Corp | Phase 2 |
| Apabetalone for Pulmonary Arterial Hypertension | Institut universitaire de cardiologie et de pneumologie de Québec, University Laval | Phase 2 |
Clinical Trial Summary for Apabetalone
Top disease conditions for Apabetalone
Top clinical trial sponsors for Apabetalone
US Patents for Apabetalone
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Apabetalone | See Plans and Pricing | Pharmaceutical compositions for substituted quinazolinones | Resverlogix Corp. (Calgary, Alberta, CA) | See Plans and Pricing |
| Apabetalone | See Plans and Pricing | Compositions and therapeutic methods for the treatment of complement-associated diseases | Resverlogix Corp. (Calgary, Alberta, CA) | See Plans and Pricing |
| Apabetalone | See Plans and Pricing | Anti-inflammatory agents | Resverlogix Corp. (Calgary, Alberta, CA) | See Plans and Pricing |
| Apabetalone | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| Apabetalone | See Plans and Pricing | Chemokine receptor modulators and uses thereof | FLX Bio, Inc. (South San Francisco, CA) | See Plans and Pricing |
| Apabetalone | See Plans and Pricing | Therapy for promoting cell growth | MOLEAC PTE. LTD. (Singapore, SG) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Apabetalone
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Apabetalone | Australia | AU2012330885 | 2031-11-01 | See Plans and Pricing |
| Apabetalone | Canada | CA2851996 | 2031-11-01 | See Plans and Pricing |
| Apabetalone | China | CN103945848 | 2031-11-01 | See Plans and Pricing |
| Apabetalone | Denmark | DK2773354 | 2031-11-01 | See Plans and Pricing |
| Apabetalone | European Patent Office | EP2773354 | 2031-11-01 | See Plans and Pricing |
| Apabetalone | Spain | ES2745471 | 2031-11-01 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
